KetoSwiss

Sections Biotech
Funding π°
Total $6.4M
Select investors William K Warren Foundation, R42 Group, Healthspan Capital, Ortho Innovations, Baszucki Group
Key people π§βπ€βπ§
- Dr. Elena Gross - Founder & CEO/CSO
- Dr. Sebastian Hersberger - CFO
- Aleksandra Cywinska - Business Development Manager
- Katharina Haar - Marketing Manager
- Aditya Shah - US General Manager
Highlights β
- Solving the problem: Migraine affects around 1 billion people worldwide, and while it is the most common neurological disorder, solutions targeting the root cause are lacking. KetoSwiss' first flagship product is made for the dietary management of migraine, and it's called MigraKet.
- Better than glucose: Due to modern carbohydrate-rich diets, our brains rely almost exclusively on glucose. This contributes to an energy deficiency in the brain and in turn neurological diseases, such as migraine or Alzheimers, which are known to have a metabolic component to it. During fasting/glucose restriction our livers produce an alternative, more effective fuel source for the brain called ketone bodies. KetoSwiss strives to bring human identical ketone bodies back into our modern world. It develops potent, clinically tested, Swiss-quality ketone body products to combat neurological civilization diseases.
- Patent-protected tech: KetoSwiss has patent protections in the EU and China, with likely plans to also secure patents in the U.S. - where the company plans to expand.
Video βΆοΈ
In the news π°
Awards & Recognitions π
Last update: August 11, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more